A longitudinal assessment of retinal function and structure in the APP/PS1 transgenic mouse model of Alzheimer's disease by Georgevsky, D et al.
RESEARCH Open Access
A longitudinal assessment of retinal
function and structure in the APP/PS1
transgenic mouse model of Alzheimer’s
disease
Dana Georgevsky1, Stephanie Retsas1, Newsha Raoufi1,2, Olga Shimoni2 and S. Mojtaba Golzan1*
Abstract
Background: A great body of evidence suggests that there are retinal functional and structural changes that occur
in Alzheimer’s disease (AD). However, whether such changes are primary or secondary remains to be elucidated.
We studied a range of retinal functional and structural parameters in association with AD- specific
pathophysiological markers in the double transgenic APP/PS1 and control mice across age.
Methods: Electroretinogram (ERG) and optical coherence tomography (OCT) was performed in APP/PS1 and wild
type (WT) control mice every 3 months from 3 to 12 months of age. For functional assessment, the a- and b-wave
of the ERG, amplitude of oscillatory potentials (OP) and the positive scotopic threshold response (pSTR) were quantified
at each time point. For structural assessment, the inner and outer retinal thickness was segmented and measured from
OCT scans. Episodic memory was evaluated at 6, 9 and 12months of age using the novel object recognition test.
Amyloid beta (Aβ) distribution in the hippocampus and the retina were visualised at 3, 6 and 12months of age. Inter-
and intra- group analysis was performed to study rate of change for each parameter between the two groups.
Results: Inter-group analysis revealed a significant difference in b-wave and OPs of APP/PS1 compared to WT controls
starting from 3months (p < 0.001). There was also a significant difference in the amplitude of pSTR between the two
groups starting from 6months (p < 0.001). Furthermore, a significant difference in the inner retinal thickness, between
the two groups, was observed starting from 9months (p < 0.001).
Conclusions: We observed an age-related decline in retinal functional and structural parameters in both APP/PS1 and
WT controls, however, inter-group analysis revealed that inner retinal functional and structural decline is exacerbated in
APP/PS1 mice, and that retinal functional changes precede structural changes in this strain. Further studies are required
to confirm whether such phenomenon occurs in humans and if studying retinal functional changes can aid-in early
assessment of AD.
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Background
Alzheimer’s disease (AD) is a chronic and progressive
neurodegenerative disease affecting nearly 44 million
people worldwide. It is the most common form of
dementia with cognitive impairment as the main clinical
manifestation [1]. Currently, diagnosis is primarily based
on patient history, neuropsychological testing and in
some cases neuroimaging, including positron emission
tomography (PET) scans and magnetic resonance im-
aging (MRI). Neuroimaging methods are expensive,
invasive and still not completely conclusive [2]. The
challenge with a pre –mortem diagnosis is the current
inability to determine whether the pathological hall-
marks of AD are firstly detectable. Furthermore, the
pathological changes occurring in the brain from early
stages through to disease progression cannot be moni-
tored. Extracellular amyloid-beta (Aβ) plaques and intra-
cellular neurofibrillary tangles are the hallmark proteins
of AD and currently are only visible on post mortem
histopathological analysis [3]. However, patients present-
ing with complaints of cognitive decline have a substan-
tial amount of damage that has already occurred for a
long time. There is evidence in the literature that initial
pathophysiological processes commence as early as 20 years
prior to clinical symptoms, indicating a large latency period
from pre-symptomatic to symptomatic AD [4]. As a result,
it has been reported that up to 15% of patients have
received an incorrect diagnosis of “probable” AD [5].
Clearly, having a definite diagnosis that is only possible
following a post-mortem histological analysis, urgently
warrants further investigation into identifying potential
early biomarkers of pre-symptomatic AD [6].
A growing body of evidence suggests sensory distur-
bances as a common complaint in patients with AD [7].
The visual system and more specifically the retina, has
received much attention in identifying AD-specific patho-
genesis that can aid-in staging the very early phases of the
disease [8–11]. Retinal dysfunction in both human studies
of AD patients as well as animal models of AD suggests a
plausible link between the retina and brain [12–15]. We
have previously reported retinal changes in 75 participants
with subjective memory complaint and found a significant
correlation between thinning of the retinal nerve fibre
layer (RNFL), vascular dysfunction and higher neocortical
Aβ scores [16]. These results were consistent with other
reports which have also shown retinal structural changes,
such as RNFL thinning and retinal ganglion cell (RGC)
loss in AD patients compared with aged matched controls
[17, 18]. A study using 13–16month old APP/PS1 mice
reported an increase in amyloid deposition in the retina,
specifically in close proximity to retinal micro vessels,
which corresponded with the levels detected in the brain
[15]. The same study reported an inner retinal functional
deficit in the AD mice compared to control mice.
The retinal abnormalities seen in AD and its’ origin or
impact are still unclear. However, it has been suggested
that the structural and functional changes observed in the
retina, such as RNFL thinning, RGC loss, and compro-
mised inner retinal function, may be due to neurotoxicity
effects from the Aβ plaques [19, 20]. With the majority of
these studies reporting their findings in participants/ani-
mals with established disease pathology, it remains unclear
whether retinal manifestations precede cerebral pathology
or occur in parallel or following AD onset. There is lim-
ited evidence in the literature with regards to the timing
of retinal changes observed in AD, with one study show-
ing amyloid plaques in the retina as early as 2.5 months of
age compared with 5months in the brain [8]. The current
study aims to explore this further by investigating markers
of retinal structure and function in association with be-
havioural and neuropathological changes of the amyloid
precursor protein- Presenilin 1 (APP/PS1) mice from 3 to
12months of age. More specifically, we studied an array of
electroretiongram parameters and retinal thickness (both
inner and outer retina) in association with progressive
AD-specific neuropathological changes in Aβ levels. Fur-
thermore, we investigated the potential link between these
parameters and levels of cognitive impairment, assessed
by the novel object recognition test. Ultimately, our aim is
to clarify whether retinal changes are observed prior, par-
allel or post neuropathological changes in the APP/PS1
mouse model of AD.
Methods
Animals
APP/PS1 mice were re-derived at the Australian phone-
mics facility (ANU Canberra). Genotyping was per-
formed, and wild type (WT) littermates were used as
controls. The genotype ratio was approximately 50:50
with mixed genders. At 12 weeks of age, the mice were
transported to the University of Technology Sydney
and housed in a temperature-controlled facility. Ani-
mals were on a 12-h light/dark cycle and were given ad
lib access to food and water as per the facilities stand-
ard operating procedures. All animal experiments were
conducted in accordance with the Australian code of
practice for the care and use of animals for scientific
purposes. Experimental work was approved by UTS
Animal Ethics Committee prior to the commencement
of experiments (ETH16–0246). APP/PS1 and WT lit-
termates (n = 70, mixed sexes roughly 50:50) were
followed longitudinally from 3 to 12 months with time-
point data captured every 3 months (ie 3, 6, 9, and 12).
For all experiments, animals were anaesthetised with an
intraperitoneal injection of ketamine (75 mg/kg) and
xylazine (10 mg/kg). The effects of xylazine were
reversed with a subcutaneous injection of atipamezole
(0.75 mg/kg).
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Optical coherence tomography (OCT)
Retinal structural changes were assessed using OCT at each
time-point (spectral domain OCT (Wasatch Photonics,
USA- field of view: > 40o, central wavelength: 800 nm,
axial resolution: 3.9 μm, transverse resolution: 4 μm
and imaging rate: 20 Hz). Animals were anaesthetised
as described previously and a drop of 1% tropicimide
(Alcon laboratories, Australia) was applied to each
eye to dilate the pupil. Animals were placed on a
heating pad during imaging to maintain ambient body
temperature. Ophthalmic gel was applied to the sur-
face of the eyes to prevent dryness from anaesthesia
as well as maintaining contact between the cornea
and the camera lens.
Scanning protocol
The scanning protocol included a 3 × 3 mm perimeter
square image of the fundus. The device or the animal
were adjusted in such way that the optic nerve head
(ONH) was centred on the image. To obtain a raster
scan of the ONH, the fundus image was transected
across the centre of the ONH to produce a B-scan
image of the retinal layers. A further two parallel B-
scans on either side of the original B-scan (125 μm
apart) was obtained (Fig. 1a).
Image segmentation
A modified version of the segmentation algorithm devel-
oped by Chiu SJ et al [21] based on graph theory was
used to segment the retina into two sections; inner and
outer retina. We observed a segmentation error of less
than 5% across all the scans in which we corrected
manually. The mean thickness of the five B-scans was
used to measure inner retinal thickness (between the
ganglion cell layer (GCL) and inner nuclear layer (INL)
and outer retinal thickness (outer plexiform layer (OPL)
and retinal pigment epithelium (RPE)) (Fig. 1).
Electroretinogram (ERG)
Animals were dark-adapted overnight prior to the
recordings. A dim red light was used to conduct the
experiments the following day. Animals were anaesthe-
tised as described previously and placed on a thermo-
statically controlled heat pad. Both eyes were dilated
using a drop of 1% tropicimide following general anaes-
thesia. The animals were placed on the heat pad of the
ERG instrument (Ocuscience, USA) and two silver cor-
neal electrodes were gently placed on the cornea and
were kept in position by placing a contact lens on top.
Stainless steel reference electrodes were inserted sub-
cutaneously on the forehead of the mouse and at the
base of the tail. The Scotopic Threshold Response
Fig. 1 OCT of the mouse optic nerve head. Top Left) five B-scans obtained across the optic nerve head, Top Right) a sample radial OCT scan,
Lower Right) results of segmenting the OCT scan into inner and outer retina
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(STR) was measured first and consisted of the mean of
30 dim flashes (3 cd.s.m-2) with 2-s intervals. This was
followed by a single bright flash ERG (30 cd.s.m-2). The
positive STR (pSTR) amplitude was measured from the
baseline to the maximum peak of the waveform at the
flash intensity. The b-wave amplitude was measured
from the trough of the a-wave to the peak of the b-
wave (Fig. 2).
Measurement of oscillatory potentials (OPs)
The OPs were isolated from the intact ERG recordings
from each eye. To mitigate effects of a-wave contami-
nants in early OPs, a digital band pass filter (60-235 Hz)
was used (MATLAB). The OP response was determined
by the summed amplitude of each OP trace (OP1, OP2,
OP3) by a blinded examiner. The amplitude (in micro-
volts) of each OP was characterised by the difference
between the peak and trough. The overall OP response
was determined through the summation of each of the
OP amplitudes (i.e OP=OP1 +OP2 +OP3).
Tissue collection
A subgroup of animals were euthanized at 3, 6 and
12 months using an intraperitoneal injection of 50% di-
luted lethabarb and saline. The eyes were enucleated and
placed in 4% paraformaldehyde (PFA) overnight for fix-
ation. The brain was dissected and followed the same
regime as the eyes. The fixed tissues were removed from
PFA the following morning and washed in phosphate
buffered saline (PBS) 3 times × 5min. The tissues were
then placed in 70% ethanol and were processed and
embedded in paraffin wax within a week. The paraffin
blocks were cut using a microtome at 5 μm thickness. A
1% and 2% Thioflavin S stain was applied on the sections
to detect Aβ in the brain’s hippocampus region and retina
(within 200 μm of the optic nerve head), respectively. All
slides were imaged using an upright fluorescent micro-
scope at 460 nm excitation.
Novel object recognition
The mice underwent the novel object recognition behav-
ioural assessment at 6, 9 and 12 month time-points. The
mice were acclimatized to the testing equipment daily
for 1 week prior to the experiment. The animals were
placed for 5 min a day in the test box in their holding
room to become comfortable with the equipment prior
to testing, to limit unwanted behavioural responses from
fear/anxiety. The experiments took place in the holding
room to avoid stress caused by new/different smells and
sounds in unfamiliar rooms. Two identical objects were
placed in a black box at opposite ends, and each mouse
was allowed 3min to explore the objects (familiarisation
phase). The objects and box were cleaned with 80%
ethanol between each animal to alleviate smells that may
distract the next animal from the test. One hour later,
one of the objects was replaced with a new “novel” ob-
ject (test phase). Again each mouse was given 3 min to
explore the objects. The recordings were then watched
by the same person to limit data variability. The D2
discrimination index was used to present results. The D2
index is a common measure used to discriminate novel
and familiar objects, and is considered as a reliable
measure as it corrects for the total exploratory activity of
each animal [22]. It is calculated based on the following
equation:
D2 ¼ novel−familiarð Þ
novel þ familiarð Þ
The D2 index, therefore, corrects for total exploratory
behaviour of each animal.
Statistical analysis
Statistical analysis was performed using Graphpad Prism 7
(San Diego, CA, USA). Data was presented as the mean
sum of the total ± standard deviation (SD). Within each
group (intra-analysis), a one-way analysis of variance
(ANOVA) was applied to assess the overall change. Tukeys
Fig. 2 ERG measurements. Right) STR trace and pSTR measurement, Left) ERG trace and a-, b-wave and OP measurements
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post-hoc analysis was used for multiple comparisons within
each group. Analysis of covariance using linear regression
analysis (ANCOVA) was applied to assess whether the
slope of change over time is different between the two
groups. An independent students t-test was used to com-
pare the mean difference for each parameter between
APP/PS1 and WT mice at each time point. Statistically
significant differences were considered at p-value < 0.05
and 95% CI.
Results
Retinal functional parameters are exacerbated in APP/PS1
mice starting from 3months
The ERG can be used to assess the functionality of various
cells in the retina through an evaluation of the electrical im-
pulse recorded at the cornea in response to a flashlight. The
major known parameters of an ERG are the a- and b –wave,
scotopic threshold response (STR) and the oscillatory poten-
tials (OP). The a-wave, the initial negative wave recorded
following a bright stimulus, is generated as a result of photo-
receptor phototransduction. The b-wave, the positive wave
following the a-wave, is generated as a result of rod bipolar
cells’ depolarization [23] in the dark-adapted retina. The
positive STR (pSTR) is known as the most sensitive re-
sponse of the dark-adapted ERG [24]. pSTR’s originate from
the inner retina and are specifically used to study RGC func-
tionality. In addition to STR, the oscillatory potentials (OP)
of the ERG is also shown to originate from the inner retina,
mainly the inner plexiform layer (IPL) [25]. We assessed and
quantified all these parameters (i.e. a-,b- wave, pSTR and
total OP) in both of the animal groups across age.
The intra-group analysis showed a significant decline in b-
wave, pSTR and total OP amplitude and a non-significant
increase in the a-wave amplitude of both APP/PS1 and WT
controls from 3 to 12months (one-way ANOVA). A
summary of these measurements and their statistical signifi-
cance are shown in Table 1.
We then assessed whether the slope of change in each
parameter over the given time period was significantly dif-
ferent between the APP/PS1 and WT mice. The ANCOVA
analysis revealed that for a-, b- wave and OPs, if the overall
slopes were identical, there is a 34.7, 8.3 and 24.2% chance,
respectively, for randomly choosing data points with slopes
this different. This suggests that the differences between
the slopes (i.e. rate of change) are not significant (p = 0.3 [a-
wave], p = 0.08 [b-wave], p = 0.2 [OP]). However, a similar
analysis applied to pSTR, revealed that there is a 0.51%
chance randomly choosing data points with slopes this dif-
ferent, suggesting the differences between the slopes are
very significant (p < 0.001) (Fig. 3).
We studied differences in each parameter between the
two groups at any given time point. The inter-group
analysis revealed a significant difference in b-wave and
OPs of APP/PS1 compared to WT controls at 3 months
(p < 0.001). There was also a significant difference in
pSTR between the two groups starting from 6months
(p < 0.001). No difference was observed in the a-wave be-
tween the two groups at any of the time-points (p = 0.1).
Retinal structural changes are exacerbated in APP/PS1
mice starting from 9months
We studied changes to the inner (NFL/INL) and outer ret-
inal (OP/RPE) thickness separately to determine whether
variations in each structure are associated with the func-
tional changes reported earlier. The intra-group analysis
revealed a significant decline in the inner retinal thickness
of APP/PS1 and WT control mice from 3 to 12months. A
similar significant change in the outer retinal thickness of
APP/PS1 mice was observed, however, the decline in the
outer retinal thickness of WT mice was in-significant. A
Table 1 Age-associated retinal functional changes in APP/PS1 and WT mice*
Time-point (months) a-wave (μv) b-wave (μv) pSTR (μv) Total OP (μv)
APP/PS1
3 − 157.6 ± 38 217.5 ± 40a,c 123 ± 22a,b,d 173.5 ± 29b,d
6 −136.7 ± 28 174.7 ± 35 77.1 ± 15a,b 119.3 ± 29b
9 − 118.9 ± 38 146.2 ± 43a 66.5 ± 8b 92.9 ± 30d
12 −116 ± 57 107.7 ± 37c 49.8 ± 12d,b 98.6 ± 24d
p-value (ANOVA) 0.1 < 0.001 < 0.0001 < 0.0001
WT
3 − 144.5 ± 45 174.6 ± 31a 112.9 ± 9b,c 117.1 ± 29b,c
6 −144.3 ± 30 155 ± 21a 99.4 ± 18 a 109.1 ± 23a,b
9 − 135.4 ± 29 137.6 ± 34a 83.4 ± 16b,a 80.7 ± 24b,a
12 − 123.2 ± 33 118 ± 31c 74.8 ± 11c,a 68.5 ± 18c,b
p-value (ANOVA) 0.2 < 0.001 < 0.001 < 0.001
*Tukeys post-hoc analysis. Shared subscripts represent statistically significant differences: a = p < .05, b = p < .01, c = p < .001, d = p < .0001
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summary of these measurements and their statistical
significance are shown in Table 2.
Similar to the retinal function, we assessed whether
the slope of change in inner and outer retinal thickness
over the given time period was significantly different
between the APP/PS1 and WT mice. For inner and
outer retinal thickness, results from the ANCOVA
analysis revealed that if the overall slopes were identi-
cal, there is a 0.09, and 0.5% chance, respectively, for
randomly choosing data points with slopes this differ-
ent. This suggests that the differences between the
slopes (i.e. rate of change) are significant (p < 0.0001
[inner retina], p < 0.01 [outer retina]) (Fig. 4).
Finally, the inter-group analysis revealed a significant
difference in the inner retinal thickness of APP/PS1
compared to WT controls starting at 9 months (p <
0.001). There was also a significant difference in the
outer retinal thickness between the two groups at 12
months (p < 0.01).
Aβ plaques were observed in the hippocampus and
retina of APP/PS1 starting from 3 and 6months,
respectively
At 3, 6 and 12 months, five animals from each group
was randomly selected, euthanized and sagittal sections
of the retina and hippocampus imaged to determine Aβ
distribution. Aβ was present in the hippocampus from
3months and appeared in the retina, mainly in the
inner nucleus layer (INL) from 6 months of age. Aβ dis-
tribution increased with ageing in the hippocampus and
inner retina, mainly ganglion cell layer (GCL), in the
APP/PS1 mice (Fig. 5). In contrast, no Aβ was observed
in the WT group (Additional file 1: Figure S1).
Fig. 3 Slope analysis (ANCOVA) for all functional parameters. A significant difference in the slope of decline was only observed in pSTR,
suggesting that this parameter’s decline is exacerbated in the APP/PS1 group (n = 15 per group, per time-point)
Table 2 Age-associated retinal structural changes in APP/PS1
and WT mice*
Time-point (months) Inner retina Outer retina
APP/PS1
3 31.2 ± 0.8b,d 54.7 ± 1.4a,b
6 30 ± 1.1b 53 ± 1.9
9 29 ± 1b 52.1 ± 2a
12 28.5 ± 0.7d,b 51 ± 2.3b
p-value (ANOVA) < 0.0001 < 0.01
WT
3 31.3 ± 0.7a,b 54.1 ± 1
6 30.5 ± 0.9 53.9 ± 1.7
9 30.4 ± 0.7a 53.5 ± 1.5
12 30.1 ± 0.9b 53.1 ± 1
p-value (ANOVA) < 0.01 0.1
*Tukeys post-hoc analysis. Shared subscripts represent statistically significant
differences: a = p < .05, b = p < .01, c = p < .001, d = p < .0001
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No significant change in cognition from 6 to 12months
of age
We observed a non-significant decline in the D2 index of
APP/PS1 and a non-significant increase in the D2 index of
WT mice, from 6 to 12months (Fig. 6). ANCOVA ana-
lysis also revealed a non-significant difference between the
sloped of the two groups (Additional file 1: Figure S2).
Discussion
In this study we investigated an array of retinal func-
tional and structural changes in the APP/PS1 double
transgenic mouse model of AD and WT control mice
over 12 months. Our results suggest that there is an
overall age-dependent decline in retinal functional and
structural parameters, however, inner retinal functional
and structural damage seems to be accelerated in the
APP/PS1 group. More specifically, we observed a signifi-
cant difference in pSTR amplitude between APP/PS1
and WT controls starting from 6months with a
significant inner retinal thinning following in the APP/
PS1 from 9months. To our knowledge, this is the first
study to characterise major functional and structural
parameters in the retina of the APP/PS1 mice,
longitudinally.
The ERG is used to assess various retinal cellular
response to a light stimulus. Consistent with previous
reports [26, 27], we found a significant age-dependent
decline in ERG parameters in both groups. A significant
reduction in pSTR amplitude and ERG latency has also
been reported in the symptomatic stage of the same
strain previously [15, 28] . We studied ERG parameters
in both groups over 12 months and found that the rate
of decline was only significant in the pSTR of the APP/
PS1 compared to WT controls. This suggests that the
disease phenocopy has significantly altered RGC func-
tionality. This is somewhat not surprising, as RGC loss
is a known retinal pathology of AD [29]. When ERG
parameters were compared between the two groups for
any given time-point, we found a significant difference
Fig. 4 Slope analysis (ANCOVA) for all inner and outer retinal thickness. A significant difference in the slope of decline was observed in both
outer and inner retinal thickness, suggesting that structural damage is exacerbated in the APP/PS1 group (n = 15 per group, per time-point)
Fig. 5 Aβ distribution in the hippocampus and retina of the APP/PS1 mice at 3,6,12 months of age (Dentate Gyrus, CA1-CA3 regions of the
hippocampus and retinal layers are shown)- Scale bar for hippocampus and retina is 100 μm and 20 μm, respectively. An increase in Aβ levels in
both regions were observed. Retinal Aβ was observed in the inner/outer retinal regions from 6months and was more pronounced in the GCL by
12months of age. (Images for WT in Additional file 1: Figure S1)
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in the outer retina parameters early on in the disease
process (i.e. 3 months) with inner retinal function
decline to reach significant status only from 6months.
While a reduction in outer retinal ERG amplitude has
been reported in AD patients [30], we could not find
any other study that has specifically characterised ERG
changes in early AD or during mild cognitive impair-
ment. This led us to hypothesise that the significant
difference in outer retinal parameters may be attributed
to a different starting baseline recording.
There are several studies that have investigated retinal
structural changes and more specifically retinal nerve
fibre layer (RNFL) thickness in AD [31–33]. Assessed by
optical coherence tomography (OCT), a non-invasive
and readily available tool, most studies have reported a
significant reduction in mean RNFL thickness in Mild
Cognitive Impairment and AD compared to healthy con-
trols [34]. Results from animal studies have been inconclu-
sive with Perez [35] reporting a non-significant neuronal
cell loss in the retina based on retinal layer thickness of
APP/PS1 mice, while Liu [36] reported a significant
decrease in the thickness of the retina in Tg2576 mice in
comparison with WT controls (P = 0.0086). Consistent with
the latter, our results showed that there was a significant
age-related reduction in the inner retinal thickness of APP/
PS1 and WT control mice from 3 to 12months. Further-
more, there was a significant difference between the inner
and outer retinal thickness of APP/PS1 and WT mice start-
ing from 9 and 12months, respectively.
Retinal Aβ deposition in 12months old APP/PS1 mice
has been reported before [37]. More interesting, Koronyo
has shown deposition of retinal plaques precede the brain in
the APP/PS1 mice (2.5months vs 5months) [8]. In this
study, we observed retinal Aβ starting from 6months (vs 3
months in the hippocampus), however, the discrepancy
between our findings and the aforementioned report maybe
due to the different Aβ staining method used. Koronyo has
developed and used a curcumin based compound to visual-
ise Aβ (and its isoforms), whereas we have used the more
common Thioflavin S approach which can only visualise
neuritic plaques. Thioflavin S, a homogenous dye, selectively
binds to the beta-sheets of proteins, and as a result, it under-
goes a shift in its emission wavelength upon binding to olig-
omers. Thioflavin S cannot bind to monomeric isoforms
and therefore cannot be detected using fluorescence imaging
[38, 39]. We initially observed Thioflavin S positive Aβ in
the outer plexiform and inner nuclear layer of the retina. By
12months of age, Aβ appeared in all of the layers of the
inner retina with the majority observed in the GCL.
Previous reports have shown cognitive impairment as a
late occurrence of the APP/PS1 mice in the Morris water
maze starting from 7 to 8 months [40, 41]. We assessed
cognitive impairment using the NOR test. While Zhang
[42] has shown that both the NOR and the Morris water
maze work equally well in the cognitive evaluation of
APP/PS1 mice, however, results from a current meta-ana-
lysis [43] suggest that there is no significant association
between experimental evaluation of cognitive deficits and
quantified cerebral Aβ levels in these animals. Our results
also confirm this; we found a non-significant decrease in
the recognition index of the APP/PS1 mice from 6 to 12
months of age. Simultaneously, there was a non-signifi-
cant increase in the recognition index of the WT control
mice for the same period.
Our study has a few limitations. First, the animal model
used in this study, the double transgenic APP/PS1 mouse
model of AD, is a representative of the familial subform of
AD that some would refer as a strain only be generalised to
the familial subform only. However, our study was aimed at
investigating the association between physiological retinal
Fig. 6 Episodic memory assessment of APP/PS1 and WT mice from 6 to 12 months of age. A non-significant change in the D2 discrimination
index was observed in both group of animals (n = 15 per group, per time-point, One-way ANOVA)
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structural and functional parameters with progressive AD-
specific cerebral pathophysiological changes. Therefore, our
results may be generalised to AD broadly. Furthermore, the
number of animal models that replicate the sporadic AD is
limited, with the Octodon degus as the only animal model
of natural AD-specific neuropathology reported in the
literature [44]. Second, as the main aim of our study was to
identify early retinal changes in AD, therefore we only aged
the animals up until 12months. Given that neuronal loss,
based on the phenotype, occurs starting at around 17
months, it might be interesting to age these animals further
to determine whether the changes we observed are acceler-
ated past the 17month time-point. However, most of the
current literature has already reported on retinal dysfunc-
tional and structural damage in the established aged animal
models of AD and human participants dismissing any fur-
ther need in a study past the 17month time-point. Third,
the inter-group analysis revealed an exacerbation of retinal
functional decline and structural damage in the APP/PS1
group. Given that there was an age-associated decline in
both groups, there is a potential for marginal bias in our se-
lected analysis and modelling.
Finally, the OCT device we have used in this study does
not have tracking abilities and therefore, intensity/reflect-
ance variability over time may have altered the OCT
scans. To address this and ensure OCT scans were taken
exactly at the same location, we adopted a few strategies.
1) we segmented the optic nerve head (manually) on the
fundus en face and used the B-scan that transected the
ONH exactly through the middle of the ONH as refer-
ence, 2) the distance between the B-scans, obtained on
either side of the ONH, and the reference B-scan was
measured in the Image J to ensure consistency at each
time point, and 3) to adjust for artefacts due to reflectance,
we normalized the intensity measurements of the inner
and outer retina to the RPE intensity in each animal at
each time point. However, RPE intensity at each time
point was very similar, suggesting that reflectance artifact
had minimal (if any) effect on our measurements (p = 0.2).
While the manual segmentation of the ONH may itself
lead to subjective errors, however, the combination of
strategies employed (i.e. averaging, consistency in meas-
urement locations, and intensity normalizing) minimizes
the risk of artefact altering the results.
Conclusions
In conclusion, we show for the first time that retinal dys-
function precedes retinal structural damage in APP/PS1
mouse model of AD. A significant decline in the b-wave
of ERG commenced from 3months, coinciding with
hippocampus Aβ deposition. This suggests that retinal
dysfunction occurs in parallel to pathological changes in
the brain in AD. Further, we observed a dysfunction of
the inner retina starting from 6months with structural
damage to the same region following on from 9months.
We did not observe any cognitive deficit in our cohort,
however, this maybe due to the fact that this particular
animal model does not show signs of cognitive dysfunc-
tion parallel to increased amyloid pathology.
Additional file
Additional file 1: Figure S1. No Aβ was observed in the hippocampus
and retina of the WT group for the same time-points. Figure S2. Slope
analysis (ANCOVA) for Novel Object Recognition test from 6 to 12
months. We observed no significant difference between the two animal
groups and across age. (DOCX 1024 kb)
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